The NIH whistleblower has drawn attention to the burgeoning market for telehealth services focused on GLP-1 medications, which are increasingly prescribed for weight management and metabolic health.
This surge in telehealth offerings raises questions about the adequacy of current regulatory frameworks to ensure patient safety and treatment efficacy.
As telehealth continues to evolve, stakeholders must consider the implications for healthcare delivery systems, including potential impacts on patient outcomes and resource allocation.